BiotechTube
Hummingbird Diagnostics

Hummingbird Diagnostics

Heidelberg, Germany· Est.
hummingbird-diagnostics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $32M

Overview

Hummingbird Diagnostics is a privately held, Heidelberg-based biotech founded in 2016, pioneering a novel diagnostic approach. The company's technology platform, mirCator, analyzes small RNAs from whole blood to capture signals from both the disease and the immune system's response, powered by proprietary AI and machine learning software. This integrated analysis aims to create highly sensitive and robust blood tests for early detection and management of cancer and other diseases. The company is in the development stage, building its platform and biomarker database with a seasoned leadership team from diagnostics and computational biology.

Oncology

Technology Platform

mirCator platform: An AI-powered, integrated system for analyzing small RNA biomarkers from both disease and host immune response in whole blood. It encompasses proprietary wet-lab blocking technology for NGS, automated sample processing, and a suite of AI/ML software (Classifynder, TransfoRNA) for biomarker discovery and analysis.

Funding History

2
Total raised:$32M
Series B$22M
Series A$10M

Opportunities

The global liquid biopsy and multi-cancer early detection market represents a multi-billion dollar opportunity driven by demand for less invasive, more informative diagnostics.
Hummingbird's unique integration of immune response biomarkers could provide a differentiated product for therapy selection and monitoring, particularly in the growing field of immuno-oncology, addressing a key unmet need in personalizing treatment.

Risk Factors

The core scientific premise requires extensive and costly clinical validation, with a high risk that the integrated signatures may not demonstrate sufficient clinical utility.
The company faces intense competition from well-capitalized players in the liquid biopsy space and will need to secure significant ongoing funding to reach commercialization, navigating a challenging regulatory and reimbursement landscape.

Competitive Landscape

Hummingbird competes in the crowded liquid biopsy market against large, commercial players like Guardant Health and Exact Sciences, as well as other early-detection focused biotechs like Freenome and Grail. Its key differentiation is the deliberate integration of immune system-derived signals with tumor signals, a niche not fully addressed by current ctDNA- or methylation-focused leaders.

More companies in Diagnostics & Precision Medicine →More companies in Germany →